EMA Authorised: Targretin (bexarotene) — H.A.C. Pharma

View source ↗

Summary

The European Medicines Agency authorised Targretin (bexarotene) for cutaneous T-cell lymphoma, with H.A.C. Pharma as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Targretin (bexarotene)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, T-Cell, Cutaneous. MAH: H.A.C. Pharma. Decision date: 11/08/2025